Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Februar 2025 09:00 ET | Quelle: Ensho Therapeutics

Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel Disease at ECCO 2025

MORRIS PLAINS, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for...
14. Februar 2025 09:00 ET | Quelle: Ensho Therapeutics

Ensho Therapeutics Announces Upcoming Presentation at ECCO 2025 of Phase 1, Once-Daily Dosing Data for NSHO-101, an Oral α4β7 Inhibitor for Inflammatory Bowel Disease

MORRIS PLAINS, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for...
27. Juni 2024 19:10 ET | Quelle: Ensho Therapeutics

Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

Portfolio of Oral Selective α4β7 Inhibitors Acquired from EA Pharma, Eisai’s GI Subsidiary Phase 2 Clinical Program in Ulcerative Colitis to Start in First Half of 2025 with Lead Asset Seasoned...
27. Juni 2024 19:00 ET | Quelle: Ensho Therapeutics

Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho Therapeutics

CHUO-KU, TOKYO and MORRIS PLAINS, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- EA Pharma Co., Ltd. (President, Hidenori Yabune; “EA Pharma”) and Ensho Therapeutics, Inc. (Founder, President and Chief...